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TUMOR IMMUNOTHERAPY SIDE EFFECTS 
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Summary
Implementation of immunotherapy in many cancer types has achieved positive results in tumor control and cure. The 
concept of immunotherapy is diﬀ erent in comparison with conventional tumor therapies. While chemotherapy, hormonal 
or biological therapies target tumor cells and mechanisms, immunotherapy targets host immune system. Amplifi cation of 
defending possibilities or unblocking the control of the immune reactions are used. Besides positive results in tumor control, 
enhancing immunogenicity can provoke harm to other tissues and systems in form of adverse reactions or unwanted side 
eﬀ ects of therapy.
Early recognition of side eﬀ ects is of crucial importance and prompt care can diminish the harm and severity. 
 Knowledge about side eﬀ ects is needed, therefore good education of all medical personnel included in treatment as well as 
patient education must be assured prior and thorough the treatment. Writt en guidelines are provided and easy reachable 
and must be used.
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NEPOŽELJNE POPRATNE POJAVE IMUNOTERAPIJE TUMORA
Sažetak
Provedba imunoterapije u mnogim vrstama karcinoma postigla je pozitivne rezultate u kontroli i liječenju tumora. 
Koncept imunoterapije razlikuje se u usporedbi s konvencionalnim terapijama tumora. Dok su kemoterapija, hormonska ili 
biološka terapija svojim djelovanjem usmjerena na uništenje tumorske stanice i mehanizama u tumoru, imunoterapija cilja 
imunološki sustav domaćina. Pri tome se jačaju obrambeni procesi i reakcije ili se korištenjem imunoterapije dovodi do 
deblokiranja procesa kontrole imunoloških reakcija. Osim pozitivnih rezultata u kontroli tumora, povećanje imunogenosti 
može izazvati štetu drugim tkivima i sustavima u obliku nuspojava ili neželjenih nuspojava terapije.
Rano prepoznavanje nuspojava od presudne je važnosti, a pravodobno zbrinjavanje može smanjiti oštećenje i težinu 
popratne pojave. Znanje o mogućim nuspojavama je nužno osigurati kroz dobro i sveobuhvatno obrazovanje svih medicin-
skih djelatnika uključenih u liječenje, a jednako je tako važno podučiti i s popratnim pojavama upoznati i pacijenata prije 
liječenja. Pisane smjernice pružene su i lako dostupne i moraju se koristiti.
KLJUČNE RIJEČI:  imunoterapija tumora, popratne pojave, zbrinjavanje popratnih pojava, : checkpoint inhibitori, 
anti-CTLA-4 imunoterapija
Renewed interest in immunotherapy as a po-
tent tool in the treatment of malignant solid tu-
mors and the confi rmation of eﬃ  cacy and impor-
tance has been seen in recent years. From the era 
of interferon, biotechnological progress has led to 
bett er understanding of host immune mechanisms 
and the identifi cation of factors by which the tu-
mor avoids host defense (1). These discoveries led 
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to identifi cation of possible targets in immune re-
sponse and precise therapies. Precise targeted am-
plifi cation of regulation and suppression process-
es in host cascade of T lymphocytes results in the 
suppression of the process of avoiding immune 
surveillance (2,3).
In addition to the already known mecha-
nisms of cytokine, vaccine and TIL therapy, the 
new drugs are based on infl uencing the so-called 
checkpoints or checkpoint protein inhibitory antibodies 
(2,3,4). These are immunomodulatory monoclonal 
antibodies that act through receptor blockade for 
a specifi c immune response and thus enhance the 
immune response of the host. Clinical practice in 
melanoma therapy lists two target pathways: 
CTLA 4 receptor on T lymphocyte-associated anti-
gen 4 and PD-1 T lymphocytes receptor (program-
med cell death-1), or PD-L1 (ligand).
New immunomodulatory drugs eﬃ  cacy is 
confi rmed in many studies and clinical sett ings in 
diﬀ erent tumor types, signifi cantly improving the 
results of treatment in melanoma, non small cell 
lung tumors, kidney cancer, to some extent also in 
urinary bladder tumors, triple negative breast 
cancer, and digestive system. Nowadays the most 
commonly used drugs with proven eﬃ  cacy in 
clinical practice are ipilimumab (anti CTLA-4), 
nivolumab, pembrolizumab (anti PD-1), atezoli-
zumab and durvalumab (anti PD-L1) (2,3,5).
With eﬃ  cient monitoring trough clinical 
studies and even more important after a substan-
tial time in clinical use and a representative num-
ber of patients, safety profi le of drugs is mostly 
defi ned, with less toxicity noted with anti-PD-1 
agents than ipilimumab as seen in KEYNOTE-006 
trial (5,6,7).
Most of acute side eﬀ ects are known as well 
as their potential toxicity, risks and harm to the 
patient. Due to mechanisms of action of drugs the 
observed toxicities, adverse reactions or other side 
eﬀ ects are manifested in the form of autoimmune 
reactions, infl ammation, or autoimmune diseases 
(3,5,6).
The appearance of side eﬀ ects is most com-
mon in four systems. Toxicities provoked by im-
mune system often aﬀ ect dermatological, gastro-
intestinal, endocrine system and liver provoking 
diﬀ erent types of autoimmune manifestations, or 
the itis group of disorders. Colitis, thyreoiditis, 
hypophysitis, hepatitis are among the most im-
portant and can reach diﬀ erent grade of severity 
(6). Other side eﬀ ects appear less frequently, 
but should not be neglected or forgott en because 
they may be as dangerous, as the more common 
ones, eg. pneumonitis (3,5,6,7).
Side eﬀ ects occur at diﬀ erent time points 
during the treatment, very rare at the beginning 
(8). Most occur within the fi rst 3 months of treat-
ment (86%), as a refl ection of infl ammatory pro-
cesses in organs, such as colitis, pancreatitis, pneu-
monitis, hepatitis, pituitary gland and skin mani-
festation (5,6,7,8,9,10). The majority also resolve 
within 3 months. Skin toxicities occur fi rstly, after 
2–3 weeks of therapy and they typically resolve 
fast. This group of side eﬀ ects is very common, 
around 44% of the patients treated with ipilimum-
ab are having one or several skin side-eﬀ ects like 
rash, pruritus and vast majority is grade 1–2 (7). 
Severe skin toxicity (grade 3–4) appears in less 
then 2% patients (7).
Digestive tract side eﬀ ects usually appear 
next, after 6–7 weeks, mostly as diarrhea and coli-
tis, followed by liver and endocrinopathies (thyre-
oiditis and hypophysitis most often) which can be 
diagnosed even after 9 weeks (9,10,11,12).
Some other immune-related unwanted side 
eﬀ ects include fatigue, pneumonitis, pancreatitis, 
arthralgia, enteritis, encephalitis, Guillain-Barre 
syndrome, myasthenia gravis-like syndrome, oc-
cular immunopathies and autoimmune-induced 
bone marrow suppression (3,13).
Previous clinical practice has shown that ear-
ly detection and recognition of symptoms is most 
important. With rapid interventions such as appli-
cation of corticosteroids and temporary treatment 
withdrawal, adverse events are mostly reversible 
and after a recovery in majority of patients can 
continue with their therapy (3,9). However, if they 
are not identifi ed early enough, they can develop 
into complex and serious grade events and be-
come potentially life-threatening. This stage of 
 severity requires hospitalization, possible inten-
sive care, application of immunosupressive drugs 
(3,5,14).
Therefore, a good education of medical staﬀ , 
from general practitioners through emergency 
physicians to oncologists and oncology staﬀ  of dif-
ferent profi les that cares for patients treated with 
immunotherapy is needed. This also includes radi-
ologists, gastroenterologists, endocrinologists, neu-
rologists, lung specialists who can be the fi rst from 
whom the patient will turn to in an emergency.
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The guidelines are fairly accessible. Most of 
them are simple, in form of convenient tabular 
views and algorithms explaining symptoms, 
needed steps and recommendations according to 
side eﬀ ect grade and severity (3,5,9). As ipilimum-
ab is in clinical use for the longest period, most of 
the recommendations are based on knowledge 
about its adverse reactions, but many may also be 
applied to reactions on treatment with PD-1 in-
hibitors. Very detailed and user friendly recom-
mendations are provided in SPC fl yers of all drugs 
(Summary of Product Characteristics) (15,16).
Some of the pharmaceutical companies have 
provided patient identity card for their medi-
cations (as for example pembrolizumab). Those 
cards are given to patients who are instructed to 
carry them all the time and in case of emergency 
show the card to the medical personnel addressed 
for help. The card provides a quick short summa-
ry of important facts about the treatment and side 
eﬀ ects for medical staﬀ  and instructions who and 
when to contact (16).
Detailed and comprehensible information 
must be oﬀ ered to each patient before and during 
the treatment (3). It is of great importance to warn 
the patient and stress the necessity for immediate 
referral and medical att ention in the event of a dis-
order or discomfort. The oncologist must reassure 
the patient that reporting the side eﬀ ect does not 
lead to certain permanent treatment withdrawal. 
We must not forget that patients often desire to 
achieve the full eﬀ ect of treatment and are in per-
manent fear of possible treatment interruption, es-
pecially if they think this drug is their only option. 
It can happen that a patient knowingly suppresses 
or minimizes side eﬀ ects, continues the treatment 
at any cost and seeks for help only when side ef-
fects are manifested in advanced form of serious 
adverse event, and thus the outcome and possibil-
ity to resolve them becomes very uncertain.
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